下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認領
文檔簡介
1、Product Data SheetCediranibCat. No.: HY-10205CAS No.: 288383-20-0分式: CHFNO分量: 450.51作靶點: VEGFR; Autophagy; PDGFR作通路: Protein Tyrosine Kinase/RTK; Autophagy儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 49 mg/mL (108.77 mM)H2O : 0.1 mg/mL (insoluble)* means sol
2、uble, but saturation unknown.SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 2.2197 mL 11.0985 mL 22.1971 mL5 mM 0.4439 mL 2.2197 mL 4.4394 mL10 mM 0.2220 mL 1.1099 mL 2.2197 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。儲備液的保存式和期限:-80C, 6 months; -20C, 1 month。-80C 儲存時,請在 6 個內(nèi)使,-20C 儲存時,
3、請在 1 個內(nèi)使。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍浮R韵氯芙獍付颊埾劝凑?In Vitro 式配制澄清的儲備液,再依次添加助溶劑:為保證實驗結(jié)果的可靠性,澄 的儲備液可以根據(jù)儲存條件,適當保存;體內(nèi)實驗的作液,建議您現(xiàn)現(xiàn)配,當天 使; 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可 以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2 mg/mL (4.44 mM); Clear solution此案可獲得 2 mg/
4、mL (4.44 mM,飽和度未知) 的澄清溶液。以 1 mL 作液為例,取 100 L 20.0 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中,混合均勻;向上述體系中加50 L Tween-80,混合均勻;然后繼續(xù)加 450 L 理鹽定容 1 mL。Page 1 of 2 www.MedChemEBIOLOGICAL ACTIVITY物活性 Cediranib (AZD2171) 選擇性,有服活性的 VEGFR2 抑制劑,對Flt1,KDR,F(xiàn)lt4,PDGFR,PDGFR,c-Kit的 IC50 值分別為于1, 于3,5,5,36,2nM。IC & Target F
5、lt-1 KDR Flt-4 PDGFR5 nM (IC50) 1 nM (IC50) 3 nM (IC50) 36 nM (IC50)PDGFR c-Kit5 nM (IC50) 2 nM (IC50)體外研究 In human umbilical vein endothelial cells, Cediranib inhibits VEGF-stimulated proliferation and KDR phosphorylationwith IC50 values of 0.4 and 0.5 nM, respectively. In a fibroblast/endothelial
6、cell coculture model of vessel sprouting,Cediranib also reduces vessel area, length, and branching at subnanomolar concentrations1.體內(nèi)研究 Once-daily oral administration of Cediranib ablates experimental (VEGF-induced) angiogenesis and inhibitsendochondral ossification in bone or corpora luteal develop
7、ment in ovary; physiologic processes that are highlydependent upon neovascularization. The growth of established human tumor xenografts (colon, lung, prostate,breast, and ovary) in athymic mice is inhibited dose-dependently by Cediranib, with chronic administration of 1.5 mgper kg per day producing
8、statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumorstreated with Cediranib reveals a reduction in microvessel density within 52 hours that becomes progressively greaterwith the duration of treatment. These changes are indicative of vascular regression withi
9、n tumors1.PROTOCOLKinase Assay 1 The inhibitory activity of Cediranib is determined against a range of recombinant tyrosine kinases KDR, Flt-1, Flt-4, c-Kit, PDGFR-, PDGFR-, CSF-1R, Flt-3, FGFR1, Src, Abl, epidermal growth factor receptor (EGFR), ErbB2, Aur-A, andAur-B using ELISA methodology1.MCE h
10、as not independently confirmed the accuracy of these methods. They are for reference only.Cell Assay 1 Proliferation of MG63 osteosarcoma cells is induced by PDGF-AA, which selectively activates PDGFR- homodimersignaling. Cells are cultured in DMEM without phenol red containing 1% charcoal stripped
11、FCS, 2 mM glutamine, and1% nonessential amino acids for 24 hours. Cediranib or vehicle is added with PDGF-AA ligand (50 ng/mL) and platesreincubated for 72 hours. Cellular proliferation is determined using a bromodeoxyuridine1.MCE has not independently confirmed the accuracy of these methods. They a
12、re for reference only.Animal Rats: Young female Alderley Park rats (6 weeks of age, Wistar derived, n=5) are dosed orally, once daily for 28 daysAdministration 1 with Cediranib (1.25-5 mg per kg per day) or vehicle. Additional rats (five per group) are treated with Cediranib (5 mgper kg per day) or
13、vehicle for 28 days and maintained for a further 28 days without treatment, to examine the effectof compound withdrawal. Histologic paraffin wax sections of the femorotibial joints and ovaries are stained with H&E.Morphometric image analysis of femorotibial sections is done, with growth plate areas
14、from both the femur and tibiain each joint being combined for an analysis of the effect of compound treatment. The area of corpora lutea in H&E-stained ovary sections is similarly determined by morphometric analysis1.Mice: Mice bearing established Calu-6 human lung tumor xenografts (0.20.01 cm3) are
15、 selected (day 0) and treatedchronically with Cediranib (6 mg per kg per day, p.o.) or vehicle. Tumors are collected (6-15 per group) 4 hours afterthe last dose of Cediranib or vehicle, on days 1, 2, 7, 14, and 21. CD31 is then detected in sections using a chromagenend point or fluorescent immunosta
16、ining1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Page 2 of 3 www.MedChemE戶使本產(chǎn)品發(fā)表的科研獻 Cell Stem Cell. 2019 Sep 5;25(3):373-387.e9. Sci Transl Med. 2018 Jul 18;10(450). pii: eaaq1093. Biomaterials. 2018 Apr;161:164-178. Neuro Oncol. 2016 Apr;18(4):5
17、38-48. Sci Signal. 2015 Dec 8;8(406):ra125.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatmentof cancer. Cancer Res, 2005, 65(10), 4389-4400.2. Zhang L, et al. Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astroc
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權(quán)或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 科學探究物質(zhì)的比熱容課件定稿新版滬科
- 孕期痰多的健康宣教
- 鼻部腫瘤的健康宣教
- 《機床電氣線路的安裝與調(diào)試》課件-第4章
- 《機械制造基礎》課件-05篇 第三單元 激光加工
- 爆震性耳聾的健康宣教
- 性發(fā)育異常的臨床護理
- 《操作系統(tǒng)類型習題》課件
- JJF(陜) 075-2021 回彈儀檢定裝置校準規(guī)范
- JJF(陜) 026-2020 脈沖式電火花檢漏儀校準規(guī)范
- GB/T 42461-2023信息安全技術(shù)網(wǎng)絡安全服務成本度量指南
- 牛頓運動定律的應用(說課稿)
- 變電站電氣設備-課件
- 讀書交流ppt《做最好的自己》
- 優(yōu)秀的公司介紹ppt
- GB/T 8433-2013紡織品色牢度試驗耐氯化水色牢度(游泳池水)
- GB/T 4208-2017外殼防護等級(IP代碼)
- GB/T 10836-2021船用多功能焚燒爐
- 結(jié)直腸癌中西醫(yī)結(jié)合治療總論
- 第23課《范進中舉》課件(共27張PPT) 部編版語文九年級上冊
- 宋曉峰小品《宋鏢傳奇》劇本臺詞手稿
評論
0/150
提交評論